|Awarded On||August 18, 2021|
|Title||Recruitment of First-Time, Tenure-Track Faculty Members|
|Award Mechanism||Recruitment of First-Time, Tenure-Track Faculty Members|
|Institution/Organization||Baylor College of Medicine|
|Principal Investigator/Program Director||Chad Johnston|
|Cancer Sites||Colorectal, Gallbladder, Liver and Intrahepatic Bile Duct|
|Summary of Goals and Objectives||
The goal of this research is to access precision pharmaceuticals that can edit the microbiome to prevent microbe-associated cancers and improve therapeutic efficacy. In the last decade, the revelation that specific bacteria impact the occurrence, prognosis, and treatment of cancer has exposed a need for drugs that can target problematic microbes without compromising communities that are essential for patient health and effective immuno-therapies. In Nature, bacteria achieve this kind of selective community editing using natural products: small molecules that feature chemical structures and biological activities that have been honed through millions of years of evolution.
Over the last decade...